Protalix BioTherapeutics (PLX) Profit After Tax (2010 - 2026)

Protalix BioTherapeutics' Profit After Tax history runs 17 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 606.13% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $15.3 million (up 292.32% YoY), while the FY2025 annual figure was -$6.6 million, down 325.24% from the prior year.
• Profit After Tax for Q1 2026 stood at $18.3 million, up from -$5.5 million in the prior quarter.
• The five-year high for Profit After Tax was $19.3 million in Q2 2023, with the low at -$6.0 million in Q4 2023.
• The 5-year median for Profit After Tax is -$2.3 million (2022), against an average of $472352.9.
• The sharpest annual moves came in 2025 and 2026: Profit After Tax plunged 184.76% in 2025, then surged 606.13% in 2026.
• Protalix BioTherapeutics' Profit After Tax stood at -$3.7 million in 2022, then slumped by 61.6% to -$6.0 million in 2023, then soared by 207.45% to $6.5 million in 2024, then slumped by 184.76% to -$5.5 million in 2025, then soared by 432.79% to $18.3 million in 2026.
• Business Quant data shows PLX's Profit After Tax at $18.3 million in Q1 2026, -$5.5 million in Q4 2025, and $2.4 million in Q3 2025.